50% off all subscriptions! ... left. Order NowOrder Now

$8.22 (0%)

Volume: 0

Closed: Nov 26, 2021

Hollow Logo Score: 0.000

Adamas Pharmaceuticals Stock Forecast

$8.22 (0%)

Volume: 0

Closed: Nov 26, 2021

Score Hollow Logo 0.000
Which way will ADMS go? Request
Stop-loss: $7.90 (-3.95%)
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 53 and the stock is currently not being overbought or oversold

Adamas Pharmaceuticals stock downgraded from Buy Candidate to Hold/Accumulate after Friday trading session.
(Updated on Nov 26, 2021)

Buy or Hold candidate since 2021-10-13 Gain 1.86%

No changes to the price of Adamas Pharmaceuticals stock on the last trading day (Friday, 26th Nov 2021). During the day the stock fluctuated 0% from a day low at $8.22 to a day high of $8.22. The price has risen in 4 of the last 10 days and is up by 0.98% over the past 2 weeks.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 93.06% during the next 3 months and, with a 90% probability hold a price between $14.17 and $20.42 at the end of this 3-month period.

Signals & Forecast

The Adamas Pharmaceuticals stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $8.19 and $8.02. A breakdown below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Wednesday, November 03, 2021, and so far it has fallen -0.12%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss

Adamas Pharmaceuticals finds support from accumulated volume at $8.08 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

In general the stock tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved $0 between high and low, or 0%. For the last week the stock has had a daily average volatility of 0.42%

Our recommended stop-loss: $7.90 (-3.95%) (This stock has low daily movements and this gives low risk. There is a sell signal from a pivot top found 16 days ago.)

Is Adamas Pharmaceuticals stock A Buy?

Adamas Pharmaceuticals holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Hold/Accumulate candidate.

Current score: 0.000

Zero in score indicates that our system is expecting high volatility and risk for the following trading day. Given the latest developments, we cannot determine the next direction as it may go both ways.

Predicted Opening Price for Adamas Pharmaceuticals of Monday, November 29, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 29, 2021 Current price
$8.22 $8.22 (Undervalued)
Hold/Accumulate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 17, 2021 "Northland Securities" gave "$8.50" rating for ADMS. The price target was set to $8.15.

Volatility and Risk
Daily Average Volatility: 0.42 %
Overall Risk: Very High High Medium Low Very Low
0.42 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $8.23
Price: $8.22
Support: $8.08

ADMS Insider Trading Show all Trades



Last 100 transactions
Buy: 2 503 057 | Sell: 2 261 854 (Shares)
Date Action Amount Person Type
Nov 24, 2021 Sell 10 000 Bigham Michael Stock Option (Right to Buy)
Nov 24, 2021 Sell 10 000 Bigham Michael Common Stock
Nov 24, 2021 Sell 10 000 Mahoney David L Stock Option (Right to Buy)
Nov 24, 2021 Sell 112 781 Mahoney David L Common Stock
Nov 24, 2021 Sell 10 000 Macphee John A Stock Option (Right to Buy)
Show all Insider Trades


Last 100 transactions
Buy: 2 503 057 | Sell: 2 261 854 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 8.22 .
8.22 .
8.22 .
Current price: 8.22
Support 8.22 .
8.22 .
8.22 .

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 0 .
0 .
8.23 0.12 %
Current price 8.22
Support 8.08 -1.70%
8.07 -1.82%
8.00 -2.68%

Click to get the best stock tips daily for free!

About Adamas Pharmaceuticals

Adamas Pharmaceuticals Adamas Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The company’s lead product candidate is the ADS-5102 that is in Phase 3 clinical development for the treatment of levodopa-induced dyskinesia, a movement disorder associated with Parkinson’s disease; and in a Phase 2 clinical study for the treatment of symptoms assoc... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE